15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease

      research-article
      , PhD 1 , 2 , , , PhD 2 , 3 , , MS 2 , 4 , , MD 5
      JAMA Network Open
      American Medical Association

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This survey study examines the understanding of aducanumab and attitudes toward its potential outcomes among older Americans after the drug's approval by the US Food and Drug Administration (FDA) for the treatment for Alzheimer disease.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: not found
          • Article: not found

          An introduction to the understanding America study internet panel

            • Record: found
            • Abstract: not found
            • Article: not found

            Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab : Crisis or Opportunity?

              Author and article information

              Journal
              JAMA Netw Open
              JAMA Netw Open
              JAMA Network Open
              American Medical Association
              2574-3805
              14 February 2022
              February 2022
              14 February 2022
              : 5
              : 2
              : e2148355
              Affiliations
              [1 ]Department of Health Policy and Management, Sol Price School of Public Policy, University of Southern California, Los Angeles
              [2 ]Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles
              [3 ]Andrus School of Gerontology, University of Southern California, Los Angeles
              [4 ]Sol Price School of Public Policy, University of Southern California, Los Angeles
              [5 ]Department of Family Medicine, Keck School of Medicine, University of Southern California, Los Angeles
              Author notes
              Article Information
              Accepted for Publication: December 6, 2021.
              Published: February 14, 2022. doi:10.1001/jamanetworkopen.2021.48355
              Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Zissimopoulos J et al. JAMA Network Open.
              Corresponding Author: Julie Zissimopoulos, PhD, Associate Professor, Department of Health Policy and Management, Sol Price School of Public Policy, University of Southern California, 635 Downey Way, Verna and Peter Dauterive Hall, Los Angeles, CA 90089 ( zissimop@ 123456usc.edu ).
              Author Contributions: Dr Zissimopoulos had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
              Concept and design: Zissimopoulos, Jacobson, Borson.
              Acquisition, analysis, or interpretation of data: All authors.
              Drafting of the manuscript: Zissimopoulos, Chen.
              Critical revision of the manuscript for important intellectual content: Zissimopoulos, Jacobson, Borson.
              Statistical analysis: Zissimopoulos, Chen.
              Obtained funding: Zissimopoulos.
              Administrative, technical, or material support: Jacobson.
              Supervision: Zissimopoulos.
              Background on aducanumab approval, Food and Drug Administration process, Alzheimer disease outcomes: Borson.
              Conflict of Interest Disclosures: Dr Borson reported serving as an author of an information sheet prepared by the American Geriatrics Society for consumers and patients regarding aducanumab. No other disclosures were reported.
              Funding/Support: This work was funded by grants P30AG066589, P30AG043073, and R01AG055401 from the National Institutes of Health.
              Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
              Article
              zld210327
              10.1001/jamanetworkopen.2021.48355
              8845005
              35157058
              0f863d08-b05e-4be5-bae1-132dafcb24bb
              Copyright 2022 Zissimopoulos J et al. JAMA Network Open.

              This is an open access article distributed under the terms of the CC-BY License.

              History
              : 26 September 2021
              : 6 December 2021
              Categories
              Research
              Research Letter
              Online Only
              Public Health

              Comments

              Comment on this article

              Related Documents Log